RÉSUMÉ
A series of novel sulfonyl hydrazide based ß-carboline derivatives (SX1-SX32) were designed and synthesized, and their structures were characterized on NMR and HRMS. Their α-glucosidase inhibitory screening results found that compounds (SX1-SX32) presented potential α-glucosidase inhibitory: IC50 values being 2.12 ± 0.33-19.37 ± 1.49 µM. Compound SX29 with a para-phenyl (IC50: 2.12 ± 0.33 µM) presented the strongest activity and was confirmed as a noncompetitive inhibitor. Fluorescence spectra, CD spectra and molecular docking were conducted to describe the inhibition mechanism of SX29 against α-glucosidase. Cells cytotoxicity indicated SX29 (0-32 µM) had no cytotoxicity on 293T cells. In particular, in vivo experiments revealed that oral administration of SX29 could regulate hyperglycemia and glucose tolerance of diabetic mice. These achieved findings indicated that sulfonyl hydrazide based ß-carboline derivatives bore promising potential for discovering new α-glucosidase inhibitors with hypoglycemic activity.
RÉSUMÉ
Indole-based bis-acylhydrazone compounds can inhibit the activity of α-glucosidase and control the concentration of blood glucose. In this paper, the characteristics of three indole-based bis-acylhydrazone compounds with different inhibitory activities of α-glucosidase as well as the interaction with α-glucosidase were studied by experiments and computational simulation techniques. Enzyme kinetic and spectral experiments showed that the indole-based bis-acylhydrazone compounds were able to inhibit enzyme activity through mixed inhibition dominated by competitive inhibition, and during the binding reaction, indole-based bis-acylhydrazone compounds can quench the intrinsic fluorescence of α-glucosidase through static quenching and an aggregation of the indole-based bis-acylhydrazone with α-glucosidase produces a stable complex with a molar ratio of 1:1, and the combination of indole-based bis-acylhydrazone compounds could lead to slight change in the conformation of α-glucosidase. The theoretical simulation demonstrated that the stability of the complex systems was positively correlated with the inhibitory activity of indole-based bis-acylhydrazone compounds, and the indole-based bis-acylhydrazone compounds occupied the active site in the multi-ligand system, resulting in a significant decrease in the binding ability of starch to active amino acids. These results suggested that indole-based bis-acylhydrazone compound was expected to be a new type of α-glucosidase inhibitor.
Sujet(s)
Inhibiteurs des glycoside hydrolases , Hydrazones , Indoles , alpha-Glucosidase , alpha-Glucosidase/métabolisme , alpha-Glucosidase/composition chimique , Inhibiteurs des glycoside hydrolases/composition chimique , Inhibiteurs des glycoside hydrolases/pharmacologie , Indoles/composition chimique , Indoles/pharmacologie , Hydrazones/composition chimique , Hydrazones/pharmacologie , Cinétique , Simulation de docking moléculaire , Analyse spectraleRÉSUMÉ
Axially chiral carboxylic acids are important motifs in chiral catalysts and ligands. We herein reported the synthesis of axially chiral carboxylic acids via Pd(II)-catalyzed atroposelective C-H olefination using carboxylic acid as the native directing group. A broad range of axial chiral biaryl-2-carboxylic acids were synthesized in good yields with high enantioselectivities (up to 84% yield with 99% ee). Gram-scale reaction and further transformation reactions also provide a platform for synthetic applications of this method.
RÉSUMÉ
In the quest for potent α-glucosidase inhibitors to combat diabetes, a series of novel thiosemicarbazide-based ß-carboline derivatives (CTL1â¼36) were synthesized and evaluated. CTL1â¼36 exhibited remarkable inhibitory effects against α-glucosidase, with IC50 values ranging from 2.81 to 12.40 µM, significantly surpassing the positive control acarbose (IC50 = 564.28 µM). Notably, CTL26 demonstrated the most potent inhibition (IC50 = 2.81 µM) and was characterized as a non-competitive inhibitor. Through a combination assay with fluorescence quenching, 3D fluorescence spectra, CD spectra, and molecular docking, we elucidated that CTL26 formed a complex with α-glucosidase via hydrogen bondings and hydrophobic interactions, leading to α-glucosidase conformation changes that impaired enzymatic activity. In vivo studies revealed that oral administration of CTL26 (25 and 50 mg/kg/d) reduced fasting blood glucose levels, enhanced glucose tolerance, and ameliorated lipid abnormalities in diabetic mice. These findings positioned CTL26 as a promising candidate for the development of α-glucosidase inhibitors with anti-diabetic potential.
Sujet(s)
Carbolines , Diabète expérimental , Inhibiteurs des glycoside hydrolases , Semicarbazides , alpha-Glucosidase , Inhibiteurs des glycoside hydrolases/pharmacologie , Inhibiteurs des glycoside hydrolases/synthèse chimique , Inhibiteurs des glycoside hydrolases/composition chimique , Animaux , alpha-Glucosidase/métabolisme , Carbolines/pharmacologie , Carbolines/composition chimique , Carbolines/synthèse chimique , Semicarbazides/pharmacologie , Semicarbazides/composition chimique , Semicarbazides/synthèse chimique , Souris , Relation structure-activité , Diabète expérimental/traitement médicamenteux , Hypoglycémiants/pharmacologie , Hypoglycémiants/synthèse chimique , Hypoglycémiants/composition chimique , Structure moléculaire , Simulation de docking moléculaire , Relation dose-effet des médicaments , Mâle , Glycémie/effets des médicaments et des substances chimiques , Glycémie/métabolisme , Glycémie/analyse , HumainsRÉSUMÉ
Forty-one 1,3,4-thiadiazolyl-containing thiazolidine-2,4-dione derivatives (MY1-41) were designed and synthesized as protein tyrosine phosphatase 1B (PTP1B) inhibitors with activity against diabetes mellitus (DM). All synthesized compounds (MY1-41) presented potential PTP1B inhibitory activities, with half-maximal inhibitory concentration (IC50) values ranging from 0.41 ± 0.05 to 4.68 ± 0.61 µM, compared with that of the positive control lithocholic acid (IC50 = 9.62 ± 0.14 µM). The most potent compound, MY17 (IC50 = 0.41 ± 0.05 µM), was a reversible, noncompetitive inhibitor of PTP1B. Circular dichroism spectroscopy and molecular docking were employed to analyze the binding interaction between MY17 and PTP1B. In HepG2 cells, MY17 treatment could alleviate palmitic acid (PA)-induced insulin resistance by upregulating the expression of phosphorylated insulin receptor substrate and protein kinase B. In vivo, oral administration of MY17 could reduce the fasting blood glucose level and improve glucose tolerance and dyslipidemia in mice suffering from DM.
Sujet(s)
Diabète expérimental , Hypoglycémiants , Simulation de docking moléculaire , Protein Tyrosine Phosphatase, Non-Receptor Type 1 , Thiazolidinediones , Protein Tyrosine Phosphatase, Non-Receptor Type 1/antagonistes et inhibiteurs , Protein Tyrosine Phosphatase, Non-Receptor Type 1/métabolisme , Animaux , Humains , Hypoglycémiants/pharmacologie , Hypoglycémiants/composition chimique , Hypoglycémiants/synthèse chimique , Hypoglycémiants/usage thérapeutique , Cellules HepG2 , Souris , Thiazolidinediones/pharmacologie , Thiazolidinediones/composition chimique , Thiazolidinediones/synthèse chimique , Diabète expérimental/traitement médicamenteux , Relation structure-activité , Mâle , Thiadiazoles/pharmacologie , Thiadiazoles/composition chimique , Thiadiazoles/synthèse chimique , Antienzymes/pharmacologie , Antienzymes/composition chimique , Antienzymes/synthèse chimique , Insulinorésistance , Glycémie/effets des médicaments et des substances chimiques , Glycémie/analyse , Glycémie/métabolismeRÉSUMÉ
In order to find effective α-glucosidase inhibitors, a series of thiazolidine-2,4-dione derivatives (C1 â¼ 36) were synthesized and evaluated for α-glucosidase inhibitory activity. Compared to positive control acarbose (IC50 = 654.35 ± 65.81 µM), all compounds (C1 â¼ 36) showed stronger α-glucosidase inhibitory activity with IC50 values of 0.52 ± 0.06 â¼ 9.31 ± 0.96 µM. Among them, C23 with the best anti-α-glucosidase activity was a reversible mixed-type inhibitor. Fluorescence quenching suggested the binding process of C23 with α-glucosidase in a static process. Fluorescence quenching, CD spectra, and 3D fluorescence spectra results also implied that the binding of C23 with α-glucosidase caused the conformational change of α-glucosidase to inhibit the activity. Molecular docking displayed the binding interaction of C23 with α-glucosidase. Compound C23 (8 â¼ 64 µM) showed no cytotoxicity against LO2 and 293 cells. Moreover, oral administration of C23 (50 mg/kg) could reduce blood glucose and improve glucose tolerance in mice.
Sujet(s)
Inhibiteurs des glycoside hydrolases , Hypoglycémiants , Thiazolidinediones , Souris , Animaux , Inhibiteurs des glycoside hydrolases/composition chimique , Hypoglycémiants/composition chimique , Structure moléculaire , Relation structure-activité , alpha-Glucosidase/métabolisme , Simulation de docking moléculaire , ThiazolidinesRÉSUMÉ
Orthosiphon aristatus is a well-known folkloric medicine and herb for Guangdong soup for the treatment of rheumatism in China. Eight isopimarane-type and migrated pimarane-type diterpenoids (1-8), including a new one with a rarely occurring α,ß-unsaturated diketone C-ring, were isolated from O. aristatus. Their structures were determined by spectroscopic methods and quantum chemical calculations. Furthermore, the most abundant compound, orthosiphol K, was structurally modified by modern synthetic techniques to give seven new derivatives (9-15). The anti-rheumatoid arthritis activity of these diterpenoids were evaluated on a TNF-α induced MH7A human rheumatoid fibroblast-like synoviocyte model. Compound 10 showed the most potent activity among these compounds. Based on their inhibitory effects on the release levels of IL-1ß, the preliminary structure-activity relationships were concluded. Furthermore, western blot analysis revealed that 10 could increase the expression of IκBα and decrease the expression of NF-κB p65, and the expression levels of COX-2 and NLRP3 proteins were consequently down-regulated.
Sujet(s)
Polyarthrite rhumatoïde , Diterpènes , Orthosiphon , Humains , Orthosiphon/composition chimique , Orthosiphon/métabolisme , Abiétanes , Polyarthrite rhumatoïde/traitement médicamenteux , Facteur de nécrose tumorale alpha , Diterpènes/pharmacologie , Diterpènes/composition chimique , Facteur de transcription NF-kappa B/métabolismeRÉSUMÉ
Gemcitabine (GEM) is a standard chemotherapeutic agent for patients with pancreatic cancer; however, GEM-based chemotherapy has a high rate of toxicity. A combination of GEM and active constituents from natural products may enhance its therapeutic efficacy and reduce its toxicity. This study investigated the synergistic effects of the combination of liriopesides B (LirB) from Liriope spicata var. prolifera and GEM on human pancreatic cancer cells. The results of our study showed that the combination of LirB and GEM synergistically decreased the viability of pancreatic cancer cells. The combination also caused a strong increase in apoptosis and a strong decrease in cell migration and invasion. Furthermore, LirB combined with GEM had potent inhibitory effects on pancreatic cancer stem cells (CSCs). Studies on the mechanisms of action showed that the combination more potently inhibited protein kinase B (Akt) and nuclear factor kappa B (NF-κB), as well as the downstream antiapoptotic molecules B-cell lymphoma 2 (Bcl-2) and survivin than either agent used alone. The results of this study suggest that the combination of LirB with GEM may improve the efficacy of GEM for the treatment of pancreatic cancer.